Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gliadel

- PMLiVE

Astellas sets up regenerative medicine unit

Will spearhead company's efforts in cell-based therapies

Otsuka’s Samsca heads clutch of Japanese approvals

Astellas' Xtandi, AstraZeneca's Forxiga and Takeda's Zacras also given the green light

National Institute for Health and Care Excellence NICE logo

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer

- PMLiVE

Takeda promotes Giles Platford

Appoints him head of commercial operations, emerging markets

- PMLiVE

Xtandi filed as pre-chemo prostate cancer therapy

Astellas and Medivation look to extend uses of their prostate cancer drug

Biogen Idec building

Eisai and Biogen partner on Alzheimer’s

Will co-develop two drug candidates

- PMLiVE

Takeda CEO admits to Blopress mis-marketing

Campaign used graph indicating drug was superior to Pfizer’s Norvasc

- PMLiVE

Five companies breach ABPI code

Lundbeck, A Menarini Pharma, Bayer, HRA Pharma UK and GlaxoSmithKline named by PMCPA

- PMLiVE

Bayer raises sales predictions for new pharma products

Expects Xarelto, Eylea, Stivarga, Xofigo and Adepas to make €7.5bn at peak

Bayer symbol

Bayer buys Chinese consumer care company

Acquires Dihon Pharmaceutical as Algeta takeover closes

- PMLiVE

NICE backs new use for Bayer’s Eylea

Will go up against Novartis’ Lucentis in treatment of macular oedema in UK

Novartis day

Novartis under fire in Japan over Diovan promotion

Offices raided amid investigation into falsified data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links